U.S. FDA Accepts Filing of Hutchmed ’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

Hong Kong, Shanghai& Florham Park, NJ— Thursday, July 1, 2021: Hutchmed (China) Limited (“Hutchmed”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the U.S. Food and Drug Administration (“FDA”) has accepted its...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news